Dexamethasone Increases Pigment Epithelium-Derived Factor in Perfused Human Eyes by Perruccio, Elizabeth M. et al.
Dexamethasone Increases Pigment Epithelium-Derived Factor in
Perfused Human Eyes
Elizabeth M. Perruccio, Laura Leigh S. Rowlette, Núria Comes, Silvia Locatelli-Hoops, Luigi
Notari, S. Patricia Becerra*, and Teresa Borrás*
Section of Protein Structure and Function, Laboratory of Retinal Cell and Molecular Biology, National
Eye Institute, NIH, Bethesda, Maryland, USA
Duke University Medical Center, Durham, North Carolina, USA
Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North
Carolina, USA
Section of Protein Structure and Function, Laboratory of Retinal Cell and Molecular Biology, National
Eye Institute, NIH, Bethesda, Maryland, USA
Department of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, North
Carolina, USA
Abstract
Purpose—To investigate the effects of dexamethasone (DEX) on pigment epithelium-derived
factor (PEDF) cDNA and secreted protein in human trabecular meshwork (TM).
Methods—Anterior segment organ cultures were perfused with 0.1 μM DEX (OD) and vehicle
(OS). Primary human TM cells (HTM) were treated with DEX under similar conditions. PEDF
mRNA and secreted PEDF protein were quantitated by RT-PCR and Western blot.
Results—PEDF mRNA and secreted PEDF protein levels were significantly higher in DEX over
vehicle-treated cultures. In contrast, DEX decreased the activity of a 92-kDa gelatinolytic zymogen
in organ culture effluents.
Conclusion—DEX action in the human TM might include a PEDF-mediating pathway.
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INTRODUCTION
Glaucoma is a chronic eye disease that leads to irreversible blindness. It affects more than 70
million people worldwide, and it is most common among African Americans. Elevated
intraocular pressure (IOP) is the major risk factor for the development of glaucoma.1 This eye
pressure is created by the resistance to aqueous humor flow exerted by the trabecular meshwork
(TM), a tissue located at the anterior chamber angle formed by the iris and the cornea. A
dysfunctional TM leads to an increase in resistance, which in turn translates into elevated IOP.
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The cells of the TM are endothelial-like, embedded in extracellular matrix (ECM), and arranged
in a spongiform-like architecture.
Glucocorticoids are potent immunosuppressants and anti-inflammatory agents. Although
dexamethasone (DEX) is frequently used to treat inflammation, its administration can
adversely cause IOP elevation and glaucoma.2 One mechanism by which DEX induces
elevated IOP includes an increase in ECM deposition in the TM,3,4 which would in part cause
increased resistance to aqueous humor outflow. However, not all molecular mediators for this
process have been elucidated. Interestingly, tissue differential microarray analysis of DEX
induction of TM cells has revealed a number of candidate genes not currently associated with
DEX and/or glaucoma.5,6 One of these genes is encoded pigment epithelium-derived factor
(PEDF).5 PEDF is a potent antiangiogenic, neurotrophic, and antitumorigenic factor. This
secreted glycoprotein of 50,000 Mr is found in the interphotoreceptor matrix and vitreous and
aqueous humor of mammalian eyes.7 It has binding affinity for ECM components, such as
collagens and glycosaminoglycans.7 PEDF acts on cells from the neural retina as well as on
endothelial cells.8 Its biological activities are associated with receptor interactions at cell
surface interfaces and changes in protein expression.8 However, little is known of the PEDF
expression, distribution, and regulation in the TM.
Given that gene microarray analysis listed PEDF as a specifically DEX-induced gene in HTM
cells in culture, it was of interest to examine in detail the regulation of PEDF in the human
TM. Utilizing a perfused anterior segment model from post-mortem human donors9 and
primary human HTM cells, we investigated the PEDF mRNA and extracellular PEDF protein
levels upon challenging both the organ and cell cultures with DEX.
MATERIALS AND METHODS
Perfusion of Human Anterior Segment Organ Culture
Eyes from non-glaucomatous donors were obtained from eye banks within 36 to 40 hr post-
mortem following consent of the patients' families. Whole globes were dissected at the equator
and mounted on perfusion chambers, as described previously.9 Perfusion was conducted with
serum-free high-glucose Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad,
CA, USA). DEX (Sigma, St. Louis, MO, USA, or MP Biomedicals, Solon, OH, USA) was
prepared in absolute ethanol at 0.1 mM and diluted 1000× into fresh DMEM every other day.
Pressure was continuously monitored with a pressure transducer connected to the dish cannula
and recorded with a computerized system. Effluents were collected from the chambers just
before the treatment with DEX and at different post-treatment times, and saved at -80°C for
protein analyses. At the end of each experiment, a small wedge was fixed for
immunohistochemistry, while the remaining anterior segments were immersed in RNAlater
(Ambion, Austin, TX, USA) for subsequent TM dissection and RNA extraction.
RNA Extraction, Reverse Transcription (RT), and cDNA Quantification
TM tissue or cellular pellets were disrupted in RLT buffer and loaded onto a QIAshredder
column (Qiagen, Valencia, CA, USA). RNA extraction continued using the RNeasy Kit with
on-column, RNAse-free DNase digestion, according to manufacturer's recommendations
(Qiagen).
For the relative quantitative PCR, RT reactions were performed using random primers
(RETROscript, Ambion).10 Determination of the exponential PCR cycle was conducted with
2.5 μl RT, 0.5 μl SuperTaq polymerase (Ambion) and intron spanning PEDF primers5 (94°C,
4 min; and cycles of 94°C, 30 sec; 60°C, 30 sec; 72°C, 1 min; final extension 72°C, 4 min).
Determination of internal 18S cDNA levels was conducted using classic primer-competimers
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(Quantum RNA, Ambion) at the predetermined exponential cycle.10 Multiplex PEDF and 18S
amplifications were performed in triplicate at the predetermined linear cycle for all comparing
conditions and electrophoresed on Tris-borate 1.5% SuperAcryl Agarose (DNA Technologies,
Gaithersburg, MD, USA) containing 25 ng/ml ethidium bromide. The integrated optical
densities of the PEDF and 18S bands (811 bp and 489 bp, respectively) were captured using
the ChemiDoc System and LabWorks Software 4.0 (UVP, Upland, CA, USA).
Quantification of the differential expression of PEDF between treated and untreated samples
was accomplished by first normalizing each PEDF and MYOC value to their internal 18S
rRNA.
For the real-time Taqman PCR, RT reactions were conducted with 1 μg of total RNA in a total
volume of 25 μl of proprietary RT buffer containing random primers, dNTPs, and 62.5 U of
Multiscribe MuLV RT enzyme with RNAse inhibitor (High Capacity cDNA Kit, Applied
Biosystems, Foster City, CA, USA) following manufacturer's recommendations (25°C for 10
min, 37°C for 2 hr). Fluorescently labeled TaqMan probe/primer sets for PEDF and MYOC
genes were purchased from the Applied Biosystems TaqMan Gene Expression collection. The
PEDF probe corresponded to sequences from exons 6 and 7 (Hs01106937 m1), the MYOC
probe corresponded to sequences from exons 2 and 3 (Hs00165345 m1), and the 18S RNA
probe corresponded to sequences surrounding position nucleotide 609 (Hs99999901 s1).
Reactions were performed in 20-μl aliquots using TaqMan Universal PCR Master Mix on
AmpErase UNG (Applied Biosystems), run on an Applied Biosystems 7500 Real-Time PCR
System, and analyzed by 7500 System SDS software (Applied Biosystems). Fold-change
values between treated and untreated samples were calculated by the formula 2-ΔΔCT, where
CT is the cycle at threshold (automatic measurement), ΔCT is CT of the assayed gene minus
CT of the endogenous control (18S), and ΔΔCT is the ΔCT of the normalized assayed gene in
the treated sample minus the ΔCT of the same gene in the untreated one (calibrator). Because
of the high abundance of the 18S rRNA used as the endogenous control, and in order to get a
linear amplification, RT reactions from control and experimental samples were diluted 104
times prior to their hybridization of the 18S Taq Man probe.
Immunohistochemistry
Wedge-shaped specimens containing the TM were fixed in 4% paraformaldehyde in 0.1 M
PB, pH 7.4, for 48 hr at 4°C, embedded in Tissue-Tek OCT (Sakura Finetek, Torrance, CA,
USA) and frozen at -80°C. 10-μm meridional sections were mounted on Superfrost/Plus
microscope slides (Thermo Fisher, Waltham, MA, USA). Buffer for all incubation steps was
0.5% BSA, 0.2% Tween-20, 0.05% sodium azide in PBS. Blocking with 5% goat serum for
0.5 hr was followed by overnight incubation with monoclonal anti-human PEDF antibody
(Chemicon, Temecula, CA, USA) (1:200). Secondary anti-mouse Cy5-conjugated (Jackson
Immunoresearch, West Grove, PA, USA) was used at 1:400. Images were captured with a
Leica SP2 laser scanning confocal microscope (Exton, PA, USA).
Protein Extraction
Proteins from serum-free effluents of perfused eye anterior segments were concentrated on a
Centricon-30 (Millipore, Billerica, MA, USA). PEDF from serum containing cell culture
medium was separated from most serum proteins by cation-exchange column
chromatography11 with SP Sepharose column (Amersham Biosciences, Piscataway, MA,
USA) and 20 mM NaHPO4 (pH 6.4), 1 mM DTT, 10% glycerol, and 50 mM NaCl as
equilibration buffer. PEDF was eluted with 500 mM NaCl in equilibration buffer. Purified
samples were used immediately or stored at -80°C.
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SDS-PAGE, Western Blot Analysis and Quantification of PEDF Protein
Protein concentrations were determined using Protein Assay solution (BioRad, Hercules, CA,
USA). Equivalent amounts of protein from control or treated conditions were loaded into each
lane and resolved on 10-20% SDS-PAGE (Invitrogen). Western blot analysis was performed
according to described methods.11 Gel proteins were electrotransferred onto Protran
membranes (0.2 μm, Schleicher & Schuell Bioscience, Keene, NH, USA). Blots were
incubated with monoclonal human PEDF antibody (Chemicon) (1:1000) followed by
incubation with biotinylated secondary goat anti-mouse IgG (Vector Laboratories,
Burlingame, CA,USA) (1:1000). PEDF immunoreactive bands were visualized with an ABC
Vectastain kit (Vector Laboratories) and HRP colorimetric substrate. The density of PEDF
immunoreactive bands was measured with Scion Image software (Scion Corporation,
Frederick, MD, USA). Additionally, levels of PEDF were determined by ELISA using the
microtiter plates, standards, and antibodies provided in the PEDF kit (Bioproducts MD LLC,
Middletown, MD, USA) and following the recommendations of the manufacturer. Relative
amounts of PEDF protein were expressed as fold-change of the DEX-treated over control-
treated samples.
Cell Culture of Primary Human TM (HTM) Cells
Post-mortem human eyes were obtained as described for the organ cultures. For isolation of
HTM cells, the TMs from a single individual were dissected out from surrounding tissue,
digested with collagenase type IV (Worthington, Lakewood, NJ, USA), and processed as
previously described.5 Cells were maintained in Improved Minimal Essential Medium (IMEM,
Biofluids, Rockville, MD, USA), 10% FBS, and 50 μg/ml gentamicin (Invitrogen). These
primary cells subsist for 9-10 passages, and experiments in this study were carried out with
passages 4-6. The two primary cell lines used in this study originated from a 17-year-old
African-American male and from a 2-year-old Caucasian female (HTM-46 and HTM-95,
respectively).
Treatments with DEX were conducted two days postconfluent HTM cells in complete IMEM
at final concentrations of 0.1 μM. DEX was prepared as above, diluted into fresh complete
IMEM and added to the cells every other day. Control dishes received fresh medium containing
drug vehicle. At designated time points, cells and supernatants were collected and analyzed
for PEDF mRNA and protein.
Gelatinolytic Assays
Gelatinolytic activities were assayed by two methods: zymography using gelatin as substrate
in polyacrylamide gels, and solution gelatinolytic activity assays using DQ-gelatin as substrate,
both as described previously.12 The reaction buffer for the solution assays was 50 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 5 mM CaCl2.
RESULTS
DEX-Induced PEDF Gene Expression in Perfused Human Anterior Eye Segments
The effects of DEX on PEDF cDNA levels were investigated on perfused intact human TM
tissue. Anterior segments from three Caucasian donors (between 56 and 78 years old) were
perfused at constant flow (Ind #1, #2, and #3). The baseline outflow facility for the eyes of the
three pairs averaged 0.43 ± 0.09 (n = 6), and the facility values for each eye at the times studied
are included in Table 1. To avoid expression variations due to different genetic backgrounds
between individuals, treatments were performed with paired eyes. One eye of each pair was
perfused with 0.1 μM DEX, while its contralateral was perfused with vehicle (control). Choice
of the DEX dose was based on the calculated clinical relevant dose and time course.13
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Results from two individuals (Ind #1 and #2) showed that, after 7-8 days exposure to DEX,
the average normalized PEDF cDNA levels were 6.5 ± 0.96-fold over the vehicle-treated
control (Ind #1, n = 3, p ≤ 0.0029) and 5.2 ± 0.27 (Ind #2, n = 3, p ≤ 0.007) (Fig. 1A). The
effect of DEX on PEDF cDNA levels was similar between the two individuals. In contrast to
PEDF, the response of the glaucoma-linked and TM DEX-induced marker, the myocilin gene
(MYOC) varied between these two individuals. It showed an induction of 1.9 ± 0.37-fold (n =
3, p ≤ 0.12) in the first individual and 10.4 ± 0.75-fold (n = 3, p ≤ 0.02) in the second one (Fig.
1B). This variation has been reported before for MYOC mRNA levels from different donors.
9
PEDF Distribution in Human Trabecular Meshwork
In order to visualize the localization of the PEDF protein, wedges from the TM tissues from
the above organ cultures were used for confocal evaluation. Immunohistochemistry showed
localization of PEDF immunoreactivity in the human TM from perfused segments. In addition,
a positive correlation between DEX treatment and PEDF immunoreactivity in the TM region
was observed (Fig. 1C). DEX-perfused tissue reflected a marked increase in PEDF
immunofluorescence compared to control-perfused tissues. Serial sections immunoreacted to
secondary antibody only were negative. Our results also show that PEDF appears to be
distributed throughout the human TM tissue, and that its induction is not limited to any
particular TM region.
DEX Specifically Increases PEDF Protein in Effluents from Anterior Segments
To determine whether the DEX-induced PEDF mRNA expression was reflected on the
translated product, PEDF protein was analyzed in the media flowing through the perfused
anterior segments (effluents). Immunoblotting detected a PEDF protein of 50-kDa (Fig. 2A).
Semi-quantitative analysis revealed that the relative PEDF protein levels increased
significantly with time in effluents of DEX-perfused anterior segments over respective
untreated controls (fold protein change). Averaged PEDF levels in the effluents of Ind #1 and
#2 were 1.8 ± 0.07-, 2.2 ± 0.16-, and 6.5 ± 0.54-fold over controls at 4, 6, and 8 days of treatment,
respectively (Fig. 2B). Protein determination assays revealed a decrease in total protein
concentration over time, which was very similar in both control and DEX-treated effluents for
two sets of individuals (Fig. 2C). To further confirm our results, we determined the induction
of PEDF using a different technology. Although exposed to DEX for a shorter time period, we
performed ELISA assays (in triplicate) on the effluents of a third individual. The effluents of
the DEX-treated eye of Ind #3 showed changes in PEDF of 2.32 ± 0.27- and 3.70 ± 0.30-fold
over the vehicle-treated contralateral eye at 4 and 6 days of treatment, respectively (not shown).
Likewise, protein concentration determination assays showed a decrease in total protein
concentration over time, which was very similar in both control and DEX-treated effluents to
those observed in Ind #1 and #2 (not shown).
These results demonstrate that PEDF was secreted to the extracellular milieu of the TM and
that its levels increased specifically and progressively over perfusion time with DEX.
Effects of DEX on PEDF cDNA in Primary HTM Cell Cultures
Total RNA from DEX-and vehicle-treated HTM cells was extracted and assayed for PEDF
gene expression by semi-quantitative RT-PCR. On HTM-46, 1, 4, and 8 days after DEX
exposure, normalized PEDF cDNA levels increased 1.5 ± 0.07-fold (n 6, p ≤ 0.02), 3.0 ± 0.78-
fold (n = 5, p ≤ 0.05), and 1.9 ± 0.23-fold (n=6, p ≤ 0.01), respectively (Fig. 3A and 3B).
In the same samples, the levels of MYOC cDNA also increased with time, as reported
previously.5 After 1, 4, and 8 days of DEX exposure, normalized MYOC cDNA was 2.3 ±
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0.19-fold (n 6, p ≤ 0.005), 4.3 ± 0.82-fold (n = 5, p ≤ 0.01), and =6.9 ± 0.50-fold(n = 6, p ≤
0.01), respectively (Fig. 3C and 3D).
On the HTM-95 cell line, derived from a different individual and analyzed using different
technology (TaqMan PCR), the results had a similar trend than in cell line HTM-46. Upon
normalization to 18S, the levels of PEDF cDNA in the DEX-treated cells, which increased
with time over the untreated control, were 1.98 ± 0.12-fold (n 3) (p ≤ 0.0002) at 1 day, 2.56 ±
0.02-fold p ≤ 0.001) (n = 3) at 4 days, and 2.42 ± 0.03-fold (p ≤ 1 × 10-6) (n = 3) at day 8 (not
shown). In turn, the increased fold changes of MYOC cDNA were 10.14 ± 1.36-fold (p ≤
0.0002) (n 3) at 1 day, 61.72 ± 5.0-fold (p ≤ 1 × 10-6) (n 3) at day 4, and 100.63 ± 7.67-fold
(p ≤ 1 × 10-7) (n = 3) at day 8 (not shown). The CT values of PEDF and MYOC (before
treatment) in this cell line were 25.7 and 35.05, respectively, indicating that the relative
abundance of PEDF in cell-cultured TM cells at passage 4 is 750× higher than that of the
glaucoma marker gene MYOC (not shown). These results also offer additional support to the
hypothesis of an individual molecular response to DEX, and that the individual from whom
the HTM-95 cells were obtained was a higher responder for MYOC and a slightly lower
responder for PEDF.
Effects of DEX on PEDF Protein Levels in Primary HTM Cell Cultures
To determine the effects of DEX on PEDF protein levels, we collected the conditioned medium
from the HTM-46 cells exposed to DEX. Western blots revealed the presence of PEDF protein
of 50-kDa (Fig. 4A). Semiquantitative immunoblotting showed that the PEDF levels increased
with treatments of 0.1 μM DEX for 1, 4, 7, and 8 days over untreated controls (Fig. 4B). No
detectable differences in PEDF content were noted during the first 24 hr; however, extracellular
PEDF was consistently higher in DEX-treated cell cultures for all subsequent time points, that
is, 2.9 ± 0.003-fold, 2.5 ± 0.34-fold, and 4.0 ± 0.03-fold over controls by 4, 7, and 8 days,
respectively. Analysis of secreted PEDF by ELISA in the serum-containing medium of the
HTM-95 cells' DEX experiment showed a decrease for the first 24 hr. However, albeit at
slightly lower ratio, extracellular PEDF was consistently higher in the DEX-treated cells with
levels of 1.41 ± 0.27- and 1.56 ± 0.27-fold over the untreated controls at 4 days and 8 days,
respectively (not shown). These results demonstrate that HTM cells secreted PEDF protein
and that DEX increased PEDF levels in the extracellular milieu of these cells.
DEX Decreases Gelatinolytic Activities in Effluents from Anterior Segments
Because of the relevance of gelatinases/ metalloproteinases (MMPs) in the regulation of
outflow facility,14 and because PEDF has been shown to be a substrate for MMP-2 and
MMP-9,12 we investigated the activity of these secreted MMPs in the organ cultures treated
with DEX above. Gelatin zymography of their effluents showed that DEX significantly and
specifically decreased the 92-kDa gelatinase B zymogen (MMP9) activity with perfusion time
at all time points (Fig. 5A). The 72-kDa gelatinase A zymogen (MMP2) showed only a slight
decrease by day 2 of DEX treatment. Solution enzymatic assays of the same samples, run in
triplicate, revealed a DEX-mediated decrease in the overall gelatinolytic activity at all time
points of treatment (Fig. 5B and 5C). By 8 days, the gelatinolytic activity of the DEX-treated
cultures was less than 50% of that in control, with a trend that paralleled the 92-kDa zymogen.
Solution assays and zymograms performed in triplicate on the effluents of the perfused eyes
from the third individual showed, however, a much lower response. The decrease of
gelatinolytic activity reached statistical significance at only one time point. At this time, we
think that this difference between individuals might be a sign of a DEX individual response.
These observations are in agreement with reported DEX-mediated decreases for MMP-2 and
MMP-9 in ex-plant, non-perfused cultures using DEX concentrations five-fold over those used
Perruccio et al. Page 6













here.3 These results show that the PEDF increase was accompanied by a decrease in
gelatinolytic activities (92-kDa zymogen).
DISCUSSION
In this study, we report that the synthetic glucocorticoid DEX specifically induces PEDF gene
expression in the human TM and increases the extracellular PEDF protein levels produced by
the intact perfused tissue and by the cultured HTM cells. Our results show that the effects of
DEX on the levels of PEDF transcripts translate into increased levels of extracellular PEDF
protein. These findings indicate that DEX has a specific and direct effect on the PEDF
extracellular reservoir of the TM of the human eye. This PEDF increase may occur in vivo and
play an important role in defining the molecular pathways by which DEX influences TM
function, in particular, its effect on IOP.
The selected TM system is closer to in vivo conditions than cultured cells. In these ex vivo
organ cultures, the TM maintains its natural architecture, and the perfused media flows in a
manner that mimics the in vivo situation of aqueous humor exiting the eye by flowing through
the tissue. The protein profile of the effluents can thus be considered a representation of the
dynamic extracellular environment of the TM. In addition to PEDF, DEX perfusions induced
the glaucoma-linked MYOC and inhibited 92-kDa gelatinolytic activities (MMP-9). The DEX-
mediated induction of PEDF shows less variation among individual donors compared to
MYOC, which displays a variation that is suggested to correlate with an individual response
to stressful insults.5 Although the perfused system does not allow one to determine whether
the TM is the only tissue responsible for the increase seen in extracellular PEDF levels, similar
induction obtained in isolated HTM cells indicates that the increase observed in the effluents
is derived in great part from cells of the TM. Consistent with our results in HTM cells, we have
also found that DEX significantly induced PEDF mRNA and extracellular PEDF protein levels
in cultures of monkey retina pigment epithelial cells (unpublished observations).
Our results have biological implications for the response of the TM to DEX. The ECM of the
TM plays a key role in the development of elevated IOP in the eye.4 It is rich in collagens,
glycosaminoglycans, and proteoglycans, and contains proteinases, including matrix
metalloproteinases (MMPs).3,15 MMPs, involved in ECM remodeling, are known to directly
influence the resistance of the TM to aqueous humor outflow and subsequently affect IOP.15
Of the MMPs MMP-2 and MMP-9 degrade PEDF and abolish its activities,12 thus contributing
to its likely turnover. Interestingly, DEX downregulates MMPs3 (Fig. 5) and upregulates
protease inhibitors (TIMPs),3,6 eliciting an overall inhibition of proteolysis in the TM. Thus,
the DEX-induced increase of PEDF seen here is not only the result of a transcriptional
upregulation, but also of an upregulation at the post-translation level caused by the inhibition
of its degradation enzymes.
The upregulation of PEDF could be a counteracting effect to the ECM DEX-mediated changes
in ECM deposition and elevated IOP. PEDF has affinity for relevant TM collagens and
glycosaminoglycans7 and has been shown to specifically bind collagen type I,7 which is highly
abundant in the TM. These interactions could have positive implications on the conformation
and quality of its ECM, which could influence aqueous humor outflow and mediate DEX-
induced elevated IOP. To this effect, it is interesting to note that the levels of PEDF have been
reported to be significantly lower in the aqueous humor of individuals of increasing age16 and
in patients with advanced glaucoma.17 Furthermore, MMP-9, which degrades PEDF, has been
found significantly upregulated in the leucocytes of normal tension glaucoma patients,18 and,
more recently, MMP-9 has been genetically linked to patients with acute primary angle closure
glaucoma.19 All together, these observations appear to support the notion that low levels of
PEDF might be correlated with aging and glaucoma.
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In conclusion, we provide evidence for an induction of PEDF gene expression and elevation
of extracellular PEDF protein by DEX in human TM-perfused tissue and cultured cells. This
DEX-mediated upregulation of PEDF in the TM may contribute to the conformational integrity
of local ECM and influence IOP, or might perhaps exert a downstream systemic effect on other
tissues. Although these potential effects need to be investigated, our results provide a new
insight into DEX's influence in the human TM.
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Overproduction of PEDF in human perfused eyes. (A) Multiplex PEDF and 18S cDNAs at
linear range amplifications in two individuals (n = 3 each) (31 and 29 cycles, respectively, and
18S primer:competimer ratio 1:15). The data are PEDF fold-change mean + SEM. Inset:
Representative gel of PEDF of Ind #2 and 18S PCR products from untreated (CON) and treated
(DEX) TMs. (B) Multiplex MYOC and 18S cDNAs at linear range amplifications in two
individuals (n = 3 each) (27 cycles and 18S primer:competimer ratio 1:9). The data are MYOC
fold-change mean + SEM. Inset: Representative gel of MYOC of Ind #2 and 18S PCR products
from untreated (CON) and treated (DEX) TMs. (C) Confocal micrographs from untreated and
DEX-treated tissues cross-reacted with anti-human PEDF antibody (1:200) and Cy5-
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conjugated anti-mouse IgG (1:400). Control sections received no primary. AC: Anterior
chamber. Scale bar: 150 μm.
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PEDF protein secreted by DEX-treated perfused eyes. (A) Representative Western blot of
DEX-treated and control effluents (10 μg/lane) and purified recombinant human PEDF protein
(15 ng) cross-reacted with anti-human PEDF antibody. For each set of organ cultures, Westerns
were performed twice. (B) Fold-change of PEDF immunoreactive bands over controls obtained
after three different exposures of one blot (mean ± SEM). (C) Total protein concentration on
effluents.
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Effect of DEX on PEDF from HTM cells. (A) Representative gels of multiplex PEDF/18S
cDNAs linear amplifications at 1, 4, and 8 days. (B) Fold-change expression of PEDF on DEX-
treated versus control, normalized to 18S (mean + SEM) (each n = 6). (C) Representative gels
of multiplex MYOC/18S cDNAs linear amplifications at 1, 4, and 8 days. (D) Fold-change
expression of MYOC on DEX-treated versus control, normalized to 18S (mean + SEM) (each
n = 6).
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Effect of DEX on PEDF from HTM cells. (A) Representative Western blots (15 μg/lane) of
conditioned media by TM cells and purified recombinant human PEDF (15 ng) cross-reacted
to human PEDF antibody. Westerns were repeated twice. (B) Fold-change of PEDF
immunoreactive bands versus control (mean ± SEM).
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Gelatinolytic activity of effluents from perfused eyes. (A) Zymogram of DEX and control
(CON) effluents (10 μl/lane) on gelatin-containing gel, stained with coomassie blue. Migration
positions of 92-kDa and 72-kDa would correspond to MMP-9 and MMP-2, respectively. (B)
DEX and control (CON) effluents (10μl/well) incubated with DQ gelatin for the indicated
times. Area under the curve values of the fluorescence of the degraded gelatin at each time
point. Inset: Time course of fluorescence of the degraded gelatin for each time point.
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